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ProgenitorsThe formation of adequate masses of endocrine and exocrine pancreatic tissues during embryogenesis is
essential to ensure proper nutrition and glucose homeostasis at postnatal stages. We generated mice with
pancreas-speciﬁc ablation of the 3-phosphoinositide-dependent protein kinase 1 (Pdk1) to investigate how
signaling downstream of the phosphatidylinositol-3-OH kinase (PI3K) pathway controls pancreas
development. Pdk1-conditional knock-out mice were born with conspicuous pancreas hypoplasia, and
within a few weeks, they developed severe hyperglycemia. Our detailed characterization of the mutant
embryonic pancreas also revealed distinct temporal, cell type-speciﬁc requirements of Pdk1 activity in the
control of cell proliferation, cell survival, and cell size during pancreas development. These results thus
uncover Pdk1 as a novel, crucial regulator of pancreatic growth during embryogenesis. In addition, we
provide evidence that Pdk1 activity is required differently in mature pancreatic cell types, since
compensatory proliferation and possible mTORC2 activation occurred in exocrine cells but not in β cells
of the Pdk1-deﬁcient postnatal pancreas.
© 2009 Elsevier Inc. All rights reserved.Introduction
The mammalian pancreas is a mixed gland composed of two
distinct tissues, exocrine and endocrine. The endocrine portion of the
pancreas supplies insulin to the entire body and the exocrine portion
produces various enzymes required for the digestion of food. The
formation of adequate masses of endocrine and exocrine pancreatic
tissues during embryogenesis is thus essential to ensure proper
nutrition and glucose homeostasis during postnatal stages.
Morphogenesis of themouse pancreas beginswith the formation of
two buds, respectively positioned on the dorsal and ventral side of the
posterior foregut; these buds are clearly visible at about embryonicday
(E) 10.5, and subsequently fuse into a single organ upon rotation of the
gut. Most exocrine and endocrine pancreatic precursors initiate
differentiation at about E14.5. The exocrine cells then proliferate
extensively and start to form acini. During the last stages of embryonic
development, the endocrine cells of the pancreas begin to organize
into islets containing a core of cells that produce insulin (β cells) andigestive and Kidney Diseases,
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(Slack, 1995). Although it is now clear that various signaling pathways
regulate growth, morphogenesis, and cytodifferentiation in the
developing pancreas, how the activity of speciﬁc components of
those signaling pathways is required during pancreas organogenesis
remains unknown (Cano et al., 2007; Murtaugh and Melton, 2003).
The growth of an organ is mediated by increases in both, cell size
and cell number, through the coordinated action of cell growth and cell
cycle progression (Fingar and Blenis, 2004). Many growth factors
(including insulin and the insulin-like growth factor), activate the
phosphatidylinositol 3-kinase (PI3K) pathway, which in turn phos-
phorylates phosphatidylinositol-4,5-biphosphate (PIP2) to generate
phosphatidylinositol-3,4,5-triphosphate (PIP3). One of the most
studied signaling events controlled by PIP3 is the activation of a
group of AGC family protein kinases, including isoforms of protein
kinase B (Pkb/Akt) and the ribosomal S6 kinase (S6K), which play
crucial roles in regulating physiological processes relevant to metab-
olism, cellular growth, proliferation, and survival (Kozma and Thomas,
2002; Mora et al., 2004).
While the precise molecular mechanisms that control cell size in
distinct developing tissues remain largely unknown, these processes
most likely require the activity of the mammalian target of rapamycin
(mTOR) kinase. The mTOR signaling hub comprises a distinct set of
macromolecular complexes that respond to two independent cellular
inputs: growth factors that activate the PI3K and Pkb/Akt signaling
pathways, and nutrient availability which is sensed by the AMPK (5′
AMP-activated protein kinase) pathway (Hay and Sonenberg, 2008).
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mTORC2. mTORC1 controls cell growth and proliferation via regulat-
ing protein synthesis, whereas mTORC2 responds to growth factor
signals to activate Akt (Toker, 2008; Oldham and Hafen, 2003;
Ruvinsky and Meyuhas, 2006).
The best-characterized downstream effectors of mTor include two
parallel signaling pathways involved in translational control: the
protein S6 kinase (S6K) and the eukaryotic initiation factor 4E
(eIF4E)-binding proteins (4E-BP1 and 4E-BP2) (Fingar et al., 2002;
Hay and Sonenberg, 2008; Toker, 2008). One main effector of the
mTor/S6K pathway is the ribosomal protein S6 (rpS6), whose
phosphorylation is directly associated with regulating cell size. The
phosphorylation of rpS6 enables the efﬁcient translation of mRNA
transcripts containing a polypyrimidine tract at their 5′ transcrip-
tional start site (the TOP motif), which encodes ribosomal proteins
and other translational regulators (Jefferies et al., 1997).
The 3-phosphoinositide-dependent protein kinase 1 (Pdk1) is a
central mediator of cellular responses induced by PI3K signaling, as it
promotes the phosphorylation-dependent activation of Pkb/Akt and
S6K (Alessi et al., 1996, 1997; Biondi et al., 2001; Chung et al., 1992;
Price et al., 1992; Stockoe et al., 1997; Williams et al., 2000). The lack
of Pdk1 activity has serious consequences for early embryogenesis, as
indicated by the fact that Pdk1-nullizygous mice do not survive
beyond E9.5 and have defective formation of multiple organs (Lawlor
et al., 2002). In addition, conditional ablation approaches have
demonstrated that in distinct developing organs Pdk1 controls cell
size, proliferation, or survival in a tissue-restricted manner (Belgardt
et al., 2008; Mora et al., 2003).
Hashimoto et al. (2006) recently showed that adult mice with
β-cell speciﬁc ablation of Pdk1 (βPdk1) do not have enough β-cell
mass in their pancreata to preserve glucose homeostasis. These
alterations were consequences of poor survival, deﬁcient prolifer-
ation and lack of growth of mature pancreatic β cells (Hashimoto et
al., 2006). In this study we conditionally inactivated Pdk1 from
mouse pancreatic progenitors to investigate whether Pdk1 function
is required for some aspects of pancreas organogenesis. We report
that Pdk1 function contributes to expand the population of
pancreatic progenitors, and we provide evidence that Pdk1 controls
differently the expansion of exocrine- and β-cell masses during
development.
Materials and methods
Animals
Pdk1ﬂΔneo/ﬂΔneomice weremaintained and genotyped as previously
described (Lawlor et al., 2002). Pdx1-Cre mice (Gu et al., 2002) were
obtained from the MMRRC (UC Davis, CA). ACTB-Bgeo/ALPP (Z/AP)
mice (Lobe et al., 1999) were purchased from the Jackson Laboratory
(Bar Harbor, MA).
Processing of embryos and pancreatic tissues
Tissues from dissected embryos or pancreata from newborn or
juvenile mice were prepared for immunohistochemical analysis in
frozen sections as previously described (Wang et al., 2005). Parafﬁn-
embedded tissues were cut (5- to 6-μm sections) and prepared
for immunohistochemical analysis after deparafﬁnization through
a xylene/ethanol series and microwave-based antigen-retrieval
processes.
Histology
Parafﬁn sections were stained with hematoxylin and eosin (H&E)
for morphology analyses. Frozen sections were stained with hPLAP
following the protocol of Lobe et al. (1999).BrdU staining and TUNEL assay
Frozen sections of embryonic pancreata were processed to
visualize bromodeoxyuridine (BrdU)-labeled cells as previously
described (Wang et al., 2005). Apoptotic cell death was also detected
using the ApopTag Fluorescein In Situ Apoptosis Detection Kit
(Chemicon International) or Klenow-Frag-EL kit (EMD Biosciences)
per the manufacturers' directions.
Immunohistochemical analysis
The following primary antibodies were used: rabbit anti-amylase
(1:1,000; Sigma); goat anti-amylase (1:100; Santa Cruz); rabbit anti-
Sox9 (1:250; Chemicon International); rabbit anti-Mist1 (1:500;
provided by S. Konieczny); rabbit anti-elastase (1:2000; AbCam);
mouse anti-beta catenin (1:500; Cell Signaling); rabbit anti-synap-
tophysin (1:1000; Zymed); rabbit anti-pan-Akt (1:100; Cell Signal-
ing); rabbit anti-pS473 (Akt) (1:10; Cell Signaling); rabbit anti-p-
T308 (Akt) (1:10; Cell Signaling); rabbit anti-S6-P (1:500; Cell
Signaling); rabbit anti-glucagon (1:50; Zymed); guinea pig anti-
glucagon (1:500; Linco Research); guinea pig anti-insulin (1:250;
DAKO); rabbit anti-Pdx1 (1:1000; provided by C. Wright); rabbit
anti-phospho-histone3 (PH3) (1:250; Upstate Biotechnology); rabbit
anti-PLAP (1:100; Zymed); rat anti-uvomorulin/E-cadherin
(1:10,000; Sigma); and rat anti-Ki67 peptide (1:1000; Thermo Fisher
Scientiﬁc). The following secondary antibodies were diluted (1:200)
before use: Cy3-conjugated donkey anti-guinea pig IgG (Jackson
ImmunoResearch); Cy3-conjugated donkey anti-rabbit IgG (Jackson
ImmunoResearch); Cy3-conjugated donkey anti-goat IgG (Jackson
ImmunoResearch); Alexa 488-conjugated donkey anti-rabbit IgG
(Molecular Probes); Alexa 488-conjugated donkey anti-rat IgG
(Molecular Probes); Alexa 488-conjugated goat anti-guinea pig IgG
(Molecular Probes); AMCA-conjugateddonkeyanti-rabbit IgG (Jackson
Immunoresearch), and Alexa 488-conjugated donkey anti-mouse IgG
(Molecular Probes). Biotinylated donkey IgG antibodies (anti-rabbit or
anti-mouse; Jackson Immunoresearch) were detected by using the
VECTASTAIN Elite ABC kit (Vector Laboratories). For nuclear staining,
sections were covered with mounting medium containing 4′,6-
diamidino-2-phenylindole (DAPI) (VECTASHIELD; Vector Laborato-
ries) or counterstainedwithhematoxylin ormethyl green. Imageswere
obtained either with a Zeiss Axioskop 2microscope or with a confocal/
Multiphoton laser-scanning Zeiss LSM 510METAmicroscope. The blue
DAPI signal was excited with a Ti:sapphire IR femtosecond laser
(Coherent Inc.). Adobe Photoshop CS2 (version 9.0; Adobe Systems,
Inc.) was used to process the images.
Cell counting and morphometric analyses
Whole pancreata of wild-type and Pdk1ﬂΔneo/ﬂΔneo;Pdx1-Cre
embryos and newborns (at least 3 specimens for each stage, per
genotype)were sectioned at 10 μm. Each third (E10.5), ﬁfth (E12.5) or
tenth (E15.5, E17.5, and P0) consecutive section was incubated with
speciﬁc antibodies for the following analyses: 1) to estimate the
average pancreatic area, we counted the number of Pdx1+ cells (E10.5
specimens), or we calculated the E-cadherin+ (Ecad+) area (E12.5,
E15.5, E17.5, or P0 specimens). 2) To estimate the proliferation index,
we counted the number of Pdx1+BrdU+ or Ecad+BrdU+ double-
positive cells in sections from E10.5 or E15.5 specimens respectively,
or the number of cells labeled with anti-phosphohistone 3 (PH3)
antibodies in E17.5 sections. 3) To quantify the apoptotic index, we
counted the number of TUNEL+ cells in sections from E10.5 or E17.5
specimens. 4) To estimate the proportion of endocrine cells, we
counted the number of glucagon+ cells in E10.5 specimens, or we
calculated the insulin+ area in E15.5 or P0 specimens. 5) To estimate
the relative exocrine cell mass, we calculated the amylase+ area. 6) To
determine the size of individual cells, P2 pancreatic sections were
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(for exocrine cells) or anti-insulin and anti-Ecad antibodies (for β
cells). ImageJ 1.37v software (NIH) was used to estimate the Ecad+,
insulin+, or amylase+ areas. Data are shown as the mean number±
standard deviation (SD) of the mean. Statistical signiﬁcance was
determined using the Student's t-test (p valueb0.05 indicates
statistically signiﬁcant differences).
Non-fasting blood glucose
Blood from the tail vein was taken, and glucose levels were
measured using a CONTOUR® Blood Glucose Monitoring System
(Bayer HealthCare LLC).
Results
Analysis of Pdk1 activity in the developing mouse pancreas
Pdk1 is required for full activation of S6K and its downstream
substrate S6 (Ruvinsky and Meyuhas, 2006; Ruvinsky et al., 2005).
Therefore, the phosphorylation of ribosomal protein 6 (rpS6-P or
S6P) can be used as an indicator of Pdk1 activity. In E9.5 wild-type
embryos stained with anti-phosphorylated ribosomal protein 6
(rpS6-P or S6P), we detected Pdk1-active (S6P+) cells in the
epithelium of the emerging dorsal pancreatic bud and its associated
mesenchyme (Fig. 1A). S6P proteins were also detected in epithelial
and mesenchymal cells of E11.5, E14.5 and E18.5 wild-type
pancreatic tissues (Figs. 1B–D). At those stages, Pdk1 appeared
active in endocrine aggregates and in scattered epithelial cells (Figs.
1B–D). In E14.5 pancreata, Pdk1 was also active in cells located at
the tip of the epithelial branches, where the forming acini emerge
(Fig. 1C). S6P+ cells were also detected in islet and exocrine cells of
the postnatal day (P) 8 pancreas (data not shown). These results
indicate that PI3K signaling (and consequently, Pdk1) is active in
pancreatic tissues throughout most of organogenesis and during
postnatal stages.Fig. 1. Distribution of phosphorylated rpS6 proteins (S6P) throughout pancreas developmen
and the surrounding mesenchymal cells (arrowheads) also express S6P proteins. Inset show
(purple staining). (B–D) In pancreatic tissues dissected between E11.5 and E18.5, S6P im
arrows), endocrine clusters (yellow arrows), the emerging acini (green arrow in C), and in as
Scale bar, 50 μm.Loss of Pdk1 function results in pancreatic hypoplasia
To investigate whether Pdk1 activity is necessary for pancreas
organogenesis, we speciﬁcally deleted Pdk1 from pancreatic progeni-
tors of Pdk1ﬂΔneo/ﬂΔneo;Pdx1-Cre mice (herein called Pdk1ΔPanc mice)
using a conditional knock-out approach. Pdk1ﬂΔneo/ﬂΔneo mice, in
which exons 3 and 4 of Pdk1 are ﬂanked by loxP sites, were crossed
with Pdx1-Cre mice expressing Cre recombinase in most pancreatic
progenitors (Gu et al., 2002; Lawlor et al., 2002). To assess the extent
of Pdk1 inactivation, we analyzed the phosphorylation status of S6
proteins in E10.5–E18.5 Pdk1ΔPanc pancreatic tissues. Starting at
around E10.5, a considerable decrease in S6P immunoreactivity was
observed in the pancreatic epithelium of Pdk1ΔPanc embryos (Suppl.
Fig. 1 and data not shown). In contrast, S6P was normally detected in
mesenchymal cells surrounding the mutant pancreatic epithelium
(Suppl. Fig. 1). These results indicate that Pdk1was efﬁciently deleted
in most pancreatic progenitors of Pdk1ΔPanc embryos.
Concomitant with the observed reduction in Pdk1 activity, starting
at around E10.5 the pancreas of Pdk1ΔPanc embryos appeared
progressively smaller than this organ of wild-type littermates;
consequently, all Pdk1ΔPanc mice were born with conspicuous
pancreatic hypoplasia (Figs. 2A, B). The results of morphometric
analyses further determined that the average sizes of E10.5, E12.5,
E15.5, or P0 Pdk1ΔPanc pancreata were approximately 76%, 64%, 49%,
and 19% the average size of the corresponding wild-type organs (Fig.
2C). Histologic analyses also revealed that the pancreata of Pdk1ΔPanc
newborn mice had considerably more mesenchyme, very small islets,
and noticeably less acini than those tissues of wild-type newborns
(Figs. 2D, E). These results thus indicate that the activity of Pdk1 is
necessary for proper pancreatic growth during embryogenesis.
The mass of endocrine cells is reduced in the Pdk1-conditional null
embryonic pancreas
To investigate whether Pdk1 function is necessary for the
formation of speciﬁc pancreatic cell types, immunohistochemicalt. (A) Numerous cells of the emerging E9.5 dorsal pancreatic bud express S6-P (arrows)
s an adjacent section stained with antibodies recognizing the pancreatic marker Pdx1
munoreactivity can be observed in: cells scattered throughout the epithelium (white
sociated mesenchymal cells (arrowheads). A (inset), Cell nuclei were stained with DAPI.
Fig. 2. Pdk1ΔPanc newborn mice have severe hypoplasia of the pancreas. (A, B) The pancreas of Pdk1ΔPanc newborn mice (B) is noticeably smaller than this organ of wild-type
littermates (A). C, The severity of the hypoplasia of Pdk1ΔPanc pancreatic tissues gradually increases throughout development. Asterisks=pb0.05; n.s.=not statistically signiﬁcant
difference (as determined by the Student's t-test). (D, E) Wild-type newborn pancreata (D) have abundant exocrine acini, visible ducts (d) and newly formed islets (isl). Instead,
Pdk1ΔPanc newborn pancreata (E) have comparatively less acini, smaller islets and overabundant mesenchyme (arrowheads). (A, B) st: stomach; spl: spleen; pcrs: pancreas; duod:
duodenum. (D, E) are parafﬁn sections stained with hematoxylin-eosin. Scale bar, 50 μm.
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type pancreata. We determined that E10.5 Pdk1ΔPanc pancreata
exhibited a slight reduction in the number of glucagon-expressing
cells (i.e., the main endocrine cell type of early-developing pancreata)
(Figs. 3A, B and Table 1). Similarly, both E15.5 and newborn Pdk1ΔPanc
pancreatic tissues had a substantial reduction in the mass of insulin-
expressing β cells (i.e., the major endocrine cell type of late-
developing pancreata) (Figs. 3C, D, G, H and Table 1). Furthermore,
in the pancreas of Pdk1ΔPanc newborn mice the number of endocrine
cells expressing glucagon, pancreatic polypeptide, ghrelin, or somato-
statin also appeared substantially reduced (Figs. 3I, J and data not
shown). As a result, the islets of Pdk1ΔPanc newborns were abnormally
small and their β cells and α cells were intermingled rather than
organized into a β-cell core surrounded by anα-cell periphery (Suppl.
Figs. 2A, B and Figs. 3E, F). Importantly, the loss of Pdk1 function did
not affect the expression of various typical β cell markers (e.g., insulin,
Pdx1, Glut2, or MafA; data not shown). Therefore, we conclude that
Pdk1 activity is necessary for the expansion of embryonic pancreatic β
cells, but not for their differentiation.Loss of Pdk1-pancreatic function is associated with decreased formation
of exocrine cells
The expression of various exocrine markers (e.g., amylase,
elastase, carboxypeptidase A, or Mist1) appeared unaffected in
Pdk1ΔPanc embryonic and newborn pancreata (Fig. 4 and data not
shown). However, as indicated by our immunohistochemical and
morphometric results the pancreas of E15.5 Pdk1ΔPanc embryos
exhibited a severe deﬁcit of exocrine cells (Figs. 4A, B and Table 2).
Moreover, at birth the average Pdk1ΔPanc pancreatic exocrine mass
was only about 20% the size of that in wild-type littermates (Figs. 4C,
D and Table 2). This deﬁcient expansion of the exocrine tissue most
likely accounted for the lack of growth of the Pdk1-deﬁcient pancreas
towards the end of gestation. Therefore, we uncovered that the
function of Pdk1 is critical to produce an adequate exocrine cell mass
during pancreas development.
Analysis of the conditional mutant pancreas showed that the
loss of Pdk1 activity does not prevent formation of the pancreatic
ducts (Figs. 4C, D; data not shown). However, due to the small size
Fig. 3. Pdk1 deﬁciency decreases the production of pancreatic endocrine cells during embryogenesis. (A, B) Early pancreatic endocrine cells (glucagon+ cells, arrows) are slightly less
numerous at E10.5 in Pdk1ΔPanc pancreata (B) than in wild-type pancreata (A). (C, D) Insulin-expressing cells (arrows) are numerous at E15.5 in the pancreas of wild-type embryos
(C), but scarce in these tissues of Pdk1ΔPanc littermates (D). (E, F) The pancreas of wild-type newbornmice (E) contains numerous islets (stained with anti-synaptophysin antibodies,
arrows). However, Pdk1ΔPanc newborn pancreata only have a small number of islets of substantially reduced size (arrows in F). (G, I) The islets of wild-type newborn pancreata
enclose a large core of β cells (insulin+, arrows in E), and peripheral α cells (glucagon+, arrows in I). (H, J) The islets of Pdk1ΔPanc newborn pancreata also have β cells (arrows in H)
and α cells (arrows in J), but these cell populations are noticeably less numerous than those of wild-type pancreata. The pancreatic epithelium was visualized with anti-Pdx1
antibodies (red in A, B) or with anti-E-cadherin antibodies (green in C-J). (E, F) Cell nuclei were stained with DAPI. Scale bar, 50 μm.
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Table 1
Relative endocrine cell mass of wild-type and Pdk1ΔPanc pancreata.
E10.5 E15.5 P0
Gluc+ cell
abundancea
Gluc+ cells
relative to
WT areab
Ins+ cell
abundancec
Ins+ area
relative to
WT aread
Ins+ cell
abundancec
Ins+ area
relative to
WT aread
WT 15.2±1.1 15.2 4.8±0.6 4.8 6.2±0.9 6.2
MUT 13.1±3.3 10.0 3.3±0.4 1.6 6.8±1.4 1.3
p=0.182 p=0.04 p=0.52
a Percentage of pancreatic cells co-expressing glucagon+.
b [(glucagon+ cells)/total wild-type pancreatic cells]×100.
c Percentage of Ecad+ area co-expressing insulin+.
d [ins+ area/wild-type Ecad+ area]×100.
Table 2
Relative exocrine cell mass of wild-type and Pdk1ΔPanc pancreata.
E15.5 P0
Amyl+ cell
abundancea
Amyl+ area
relative to
WT areab
Amyl+ cell
abundancea
Amyl+ area
relative to
WT areab
WT 54.3±1.2 54.3 86.7±8.3 86.7
MUT 25.2±2.3 12.3 84.3±9.6 16.0
p=0.03 p=0.38
a Percentage of Ecad+ area co-expressing amylase+.
b [amylase+ area/wild-type Ecad+ area]×100.
290 J.J. Westmoreland et al. / Developmental Biology 334 (2009) 285–298of most ductal cells, we could not investigate any possible
quantitative changes in the ductal cell mass that could result from
the lack of Pdk1 function. Overall, we conclude that during pancreas
organogenesis Pdk1 does not participate in cell type differentiation
processes. However, Pdk1 activity is critical for the proper growth of
this organ.
Proliferation is hindered in developing β cells, but not in developing
exocrine cells, of the Pdk1-conditional null pancreas
As Pdk1 reportedly controls the proliferation of certain cell types
(Hashimoto et al., 2006; Hinton et al., 2004; Nakamura et al., 2008),
we compared the proliferation index (i.e., the percentage of cells
incorporating BrdU or expressing the mitotic marker PH3) between
pancreata of wild-type and Pdk1ΔPanc embryos.
Our quantitative results showed that, in comparison to wild-type
embryos, the pancreas of Pdk1ΔPanc embryos had fewer proliferating
cells (i.e., BrdU+Pdx1+ cells) at E10.5 (Table 3). Since the precursors
of all pancreatic cell lineages express Pdx1 at E10.5 (Gu et al., 2002),
we conclude that Pdk1 activity promotes early pancreatic growth by
controlling progenitor cell proliferation.Fig. 4. Pdk1 deﬁciency decreases the production of pancreatic exocrine cells during embryog
pancreas of wild-type embryos (A), but scarce in these tissues of Pdk1ΔPanc littermates (B). (C
cells, blue staining and arrows) and newly formed ducts (visible with anti-Sox9 antibodies,
less acini (arrows) than wild-type pancreata, and ducts (arrowheads) with relatively norm
antibodies (green staining). Scale bar, 100 μm.In the pancreas of Pdk1ΔPanc embryos we detected similar
abundance of proliferating cells at E15.5, and approximately 2-fold
more epithelial cells undergoing proliferation at E17.5 in comparison
to those tissues of wild-type littermates (Table 3). We generated
Pdk1ΔPanc;R26RLacZ embryos in which the expression of the β-gal
reporter gene indicates Cre recombinase activity (and consequently,
Pdk1 deletion; Soriano, 1999) to uncover cell types undergoing
proliferation in the Pdk1-deﬁcient pancreas. We observed co-locali-
zation of β-gal proteins in all insulin+ cells and in some, but not all,
exocrine cells in Pdk1ΔPanc;R26RLacZ pancreatic specimens dissected
betweenE17.5 and P2 (Figs. 5 and 6 and data not shown). These results
suggestmosaic deletion of Pdk1 in exocrine cells, and uniformdeletion
of this gene in β cells, in Pdk1ΔPanc pancreata.
We identiﬁed several β cells undergoing proliferation in the
pancreas of E17.5 wild-type embryos (β-gal−insulin+PH3+; Fig. 5A)
and, only rarely, no more than 1–2 proliferating β cells in this organ of
Pdk1ΔPanc;R26RLacZ littermates (β-gal+insulin+PH3+; Figs. 5B, C and
data not shown). In contrast, numerous proliferating exocrine cells
(amylase+PH3+) were observed in the pancreas of E17.5 wild-type
(Figs. 5D, D″) or Pdk1ΔPanc;R26RLacZ (Figs. 5E, E″) embryos. Most
notable, almost all Pdk1-deleted acini (i.e., β-gal+amylase+) of
Pdk1ΔPanc;R26RLacZ pancreata contained at least one exocrine cell
undergoing mitosis (Figs. 5E, E″). Therefore, we conclude that Pdk1enesis. (A, B) Elastase-expressing exocrine cells (arrows) are numerous at E15.5 in the
) The pancreas of wild-type newbornmice contains numerous exocrine acini (amylase+
red staining and arrowheads). (D) The pancreas of Pdk1ΔPanc newborn mice contains far
al appearance. (A, B) The pancreatic epithelium was visualized with anti-E-cadherin
Table 3
Proliferation index of wild-type and Pdk1ΔPanc pancreata.
E10.5 E15.5 E17.5
BrdU+ cell
abundancea
BrdU+ cell
abundance
relative to
WT
BrdU+ cell
abundanceb
BrdU+ cell
abundance
relative to
WT
PH3+ cell
abundancec
PH3+ cell
abundance
relative to
WT
WT 44.1±7.8 1.0 3.23±0.19 1.0 14.6±6.5 1.0
MUT 28.2±5.7 0.64 2.93±0.39 0.91 31.2±7.1 2.1
p=0.023 p=0.263 p=0.02
a Percentage of Pdx1+ cells co-expressing BrdU+.
b No. of BrdU+ cells per Ecad+ area (arbitrary units×103).
c No. of PH3+ cells per Ecad+ area (arbitrary units×103).
291J.J. Westmoreland et al. / Developmental Biology 334 (2009) 285–298function is necessary for β cell proliferation, but is dispensable for
exocrine cell proliferation, in the developing pancreas.
Loss of Pdk1 function decreases the survival of developing pancreatic
exocrine cells
To investigate whether increased cell death contributed to the lack
of growth of the Pdk1-deﬁcient pancreas, we compared the apoptotic
index (i.e., the percentage of TUNEL+ cells) between pancreata
of wild-type and Pdk1ΔPanc embryos. Our results showed slightlyFig. 5. Exocrine cells, but not β cells, undergo proliferation in the pancreas of E17.5 Pdk1ΔPanc
antibodies) and some exocrine cells (D″, identiﬁed with anti-amylase antibodies [green] in a
A, D″) in wild-type pancreata. (B, C) PH3 (green staining) is not expressed in the vast majori
that some epithelial cells devoid of insulin are PH3+, yellow arrows). (E″) PH3 expression (g
[green] in an adjacent section [ E]) of E17.5 Pdk1ΔPanc;R26RLacZ pancreata. (B, C, E, E″) Section
identify epithelial cells with presumptive Pdk1-deletion (red staining). (D–E″) Cell nuclei wincreased abundance of TUNEL+ cells in Pdk1ΔPanc pancreata in
comparison to wild-type pancreata at E10.5 (Table 4). On the basis of
these results, we conclude that early during pancreas organogenesis
(at around E10.5) Pdk1 activity is required to control the survival of
pancreatic progenitors.
The results of quantitative analyses uncovered signiﬁcantly more
cells undergoing apoptosis (TUNEL+ cells) in the pancreas of Pdk1ΔPanc
embryos than in this organ of wild-type littermates at E17.5 (Table 4).
We stained E17.5 wild-type or Pdk1ΔPanc;R26RLacZ pancreatic speci-
mens with speciﬁc antibodies to identify the epithelial cell types
undergoing apoptosis. In wild-type pancreatic sections we observed
lack of TUNEL staining in the vast majority of β cells (Fig. 6A) or
exocrine cells (Fig. 6D). Pdk1-deﬁcient β cells (β-gal+insulin+) were
also largely devoid of TUNEL staining (Figs. 6B, C). In contrast,
numerous Pdk1-deleted exocrine cells (β-gal+amylase+) stained
positive for TUNEL in the E17.5 Pdk1ΔPanc;R26RLacZ pancreas (green
arrow in Fig. 6B and white arrows in Figs. 6E, F). These results indicate
that Pdk1 controls the survival of exocrine cells, but not the survival of
β cells, in the embryonic pancreas.
In summary, we propose that the reduced size of Pdk1ΔPanc
newborn pancreata is a consequence of: 1) deﬁcient proliferation and
survival of early progenitors, 2) reduced proliferation of developing β
cells, and 3) increased apoptosis of developing exocrine cells.;R26RLacZ embryos. (A, D, D″) At E17.5, some β cells (A, stained in blue with anti-insulin
n adjacent section [D]) appear expressing the mitosis marker PH3 (arrows and green in
ty of β cells (arrowheads) of the E17.5 Pdk1ΔPanc;R26RLacZ pancreatic epithelium (notice
reen and arrows) is detected in exocrine cells (identiﬁed with anti-amylase antibodies
s of E17.5 Pdk1ΔPanc;R26RLacZ pancreata were stained with anti-β-gal antibodies (red) to
ere stained with DAPI. Scale bar, 25 μm.
Fig. 6. Exocrine cells, but notβ cells, undergo apoptosis in the pancreas of E17.5 Pdk1ΔPanc;R26RLacZ embryos. (A, D) Almost noβ cells (A, insulin+ [blue]) or exocrine cells (D, amylase+
[blue]) appear to undergo apoptosis (TUNEL+ staining [green]) in the pancreas of E17.5 wild-type embryos (notice that the adjacent spleen contains numerous TUNEL+ cells, green
arrows in D). (B, C) The reduced population of β cells (insulin+, blue staining and arrowheads) of E17.5 Pdk1ΔPanc;R26RLacZ pancreata is also largely negative for TUNEL staining (notice
a presumptive exocrine cell staining positive for TUNEL in B [green arrow]). (E, E″) Several exocrine cells (amylase+, blue staining) in the pancreas of E17.5 Pdk1ΔPanc;R26RLacZ
embryos are positive for TUNEL (arrows and green). (B, C, E, E″) Sections of E17.5 Pdk1ΔPanc;R26RLacZ pancreatawere stainedwith anti-β-gal antibodies (red) to identify epithelial cells
with presumptive Pdk1-deletion. (A) Cell nuclei were stained with DAPI. Scale bar, 25 μm.
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The H&E staining of some E18.5 to P0 Pdk1ΔPanc pancreata showed
entire lobes of the mutant organ with noticeably smaller acini than
those of wild-type littermates (Figs. 7A, B) and other lobes containing
both, relatively normal-sized and small-sized acini (Fig. 7C). The
variable size of the acini (i.e., small versus normal) of Pdk1ΔPanc
pancreata was likely the consequence of mosaic deletion of Pdk1 in
pancreatic exocrine progenitors, because in the larger P0 Pdk1ΔPanc;Z/
AP pancreatic specimens we detected activity of the reporter human
placental alkaline phosphatase (HPAP) in some, but not all, exocrineTable 4
Relative apoptosis of wild-type and Pdk1ΔPanc pancreata.
E10.5 E17.5
TUNEL+ cell
abundancea
TUNEL+ cell
abundance
relative to WT
TUNEL+ cell
abundanceb
TUNEL+ cell
abundance
relative to WT
WT 1.0±0.6 1.0 1.7±0.1 1.0
MUT 2.2±1.6 2.2 12.6±2.3 7.5
p=0.226 p=0.005
a Percentage of TUNEL+ pancreatic cells.
b No. of TUNEL+ cells per Ecad+ area (arbitrary units×103).acini (Suppl. Figs. 3B, C). Conversely, nearly all exocrine cells of the
smallest P0 Pdk1ΔPanc;Z/AP pancreatic specimens were HPAP+ (Suppl.
Fig. 3A). HPAP activity was also uniformly detected in the ducts and
islets of both, large and small P0 Pdk1ΔPanc;Z/AP pancreata (Suppl.
Fig. 3A).
Immunostaining of P2 Pdk1ΔPanc or wild-type pancreata with anti-
E-cadherin antibodies showed that the smallmutant acini did not have
fewer exocrine cells, but rather smaller exocrine cells than did the
wild-type acini (Figs. 7D, E). Double-immunostaining experiments
using anti-E-cadherin and anti-insulin antibodies revealed thatmost β
cells of P2 Pdk1ΔPanc pancreata were also undersized (Figs. 7G, H).
Morphometric results further established that both, the small exocrine
cells and the β cells of P2 Pdk1ΔPanc pancreata were about 50% smaller
than the corresponding cells of P2 wild-type pancreata (Figs. 7I, J). We
conclude that Pdk1 function controls the proper size of exocrine cells
and β cells during pancreas development.
Pdk1ΔPanc juvenile mice have undersized β cells and exocrine cells and
are hyperglycemic
All Pdk1ΔPanc pups thrived during the ﬁrst week after birth, though
most were slightly smaller than their wild-type littermates. However,
after P21 nearly every Pdk1ΔPanc mouse developed hyperglycemia
Fig. 7. Loss of pancreatic Pdk1 function severely reduces the size of exocrine acini, individual exocrine cells and β cells. (A–C) Some lobes in the pancreas of Pdk1ΔPanc newborn mice
contain noticeably small acini (compare the size of the acini [arrows] between A and B), whereas other lobes have both, normal-sized acini (arrowheads in C) and small-sized acini
(arrow in C). (D–H) The exocrine cells (D) and β cells (G) of wild-type newborn pancreata have a larger size andmore abundant cytoplasm than the corresponding cells of Pdk1ΔPanc
newborn pancreata (E, exocrine cells; H, β cells). (I, J) Graph shows the average relative sizes±standard deviation of P2 pancreatic exocrine cells (I) or P2 pancreatic β cells (J)
(⁎=pb0.005 versus the corresponding control value). (A–C) Parafﬁn sections were stained with hematoxylin-eosin. (D, E) The pancreatic epithelium was visualized with anti-E-
cadherin antibodies (green) and the cell nuclei with DAPI (blue). (G, H) Confocal images of frozen sections stained with anti-E-cadherin antibodies (red), anti-insulin antibodies
(green) and DAPI. Scale bar is: 50 μm (A–C), 12 μm (D, E) and 10 μm (G, H).
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295J.J. Westmoreland et al. / Developmental Biology 334 (2009) 285–298(the average blood glucose level of random-fedwild-typemice [males
and females] was 130.1±19.9 mg/dL [n=16], and that of Pdk1ΔPanc
mice [males and females] was 372.6±119.7 mg/dL [n=19;
pb0.001]). This alteration was likely caused by a severe β cell deﬁcit,
as we found that the islets of P21 Pdk1ΔPanc pancreata were minute
(Suppl. Figs. 2C, D) and their endocrine cells were clearly undersized
(Figs. 8I, J).
At P21, the Pdk1ΔPanc pancreas was remarkably smaller than this
organ of wild-type littermates (Figs. 8A, B). Similar to what we
observed at E18.5-P2, H&E staining revealed that some P21 mutant
lobes had very small acini (Figs. 8C, D) formed by undersized exocrine
cells (Figs. 8G, H). In contrast, other lobes of P21 Pdk1ΔPanc pancreata
had relatively normal-sized acini (data not shown). Sections of P23
Pdk1ΔPanc;Z/AP pancreata stained with anti-HPAP antibodies revealed
that the normal-sized acini were HPAP−, whereas the small-sized
acini and nearly all islets and ducts were HPAP+ (Suppl. Fig. 4). These
results indicate that the exocrine cells of Pdk1ΔPanc pancreata devoid
of Pdk1 function did not recover their normal size upon maturation.
Overall, our results imply a continuous, cell-autonomous require-
ment of Pdk1 function in the pre- and postnatal pancreas to maintain
the proper size of exocrine cells and β cells. Hashimoto et al. (2006)
previously reported a similar role of Pdk1 in pancreatic β cells of adult
mice.
Pdk1ΔPanc juvenile mice have compensatory proliferation in their
pancreatic acinar tissue
In the pancreas of P21 wild-type mice we observed expression of
the proliferation marker Ki67 in some exocrine cells and in a few
ductal cells or islet cells (Fig. 8E and data not shown). Conversely, in
the pancreas of Pdk1ΔPanc littermates we noticed extensive Ki67
expression throughout the exocrine tissue, particularly in those acini
with undersized exocrine cells (Fig. 8F). In these mutant tissues we
also observed Ki67 expression in some ductal cells and, only rarely, in
a few islet cells (data not shown). These observations support the
notion that Pdk1 regulates the proliferation of mature pancreatic β
cells (Hashimoto et al., 2006) and, conversely, uncover that Pdk1
activity is dispensable for proliferation in mature pancreatic exocrine
cells.
Previous results showed that in certain cell types the loss of Pdk1
function markedly stimulates the mTORC2-dependent phosphoryla-
tion of Akt at S473 (Bhaskar and Hay, 2007; Chalhoub et al., 2009;
Mora et al., 2003; Williams et al., 2000). We used antibodies
recognizing Akt phosphorylated at S473 (p-S473) to stain sections
of P21 Pdk1ΔPanc or wild-type pancreata and showed negligible Akt
phosphorylation at S473 in the wild-type tissues (Fig. 9A). Similarly,
the islets (Fig. 9C), ducts (Fig. 9C), and normal-sized acini (Figs. 9D, E)
of P21 Pdk1ΔPanc pancreata were devoid of Akt (S473) phosphoryla-
tion. In contrast, the p-S473 form of Akt was highly expressed in the
acinar regions containing small exocrine cells of P21 Pdk1ΔPanc
pancreata (Figs. 9B, F, G). This result raises the possibility that in the
absence of functional Pdk1, mTORC2 kinase was activated speciﬁcally
in the small-sized exocrine cells of Pdk1ΔPanc pancreata.
Previous experimental evidence suggested that Pdk1 prevents cell
cycle withdrawal of pancreatic β cells, at least in part, by promoting
the Akt-mediated phosphorylation and subsequent exclusion from
the nucleus of the transcription factor Foxo1 (Hashimoto et al., 2006).
Accordingly, in islets of P18 wild-type pancreata we observed Foxo1Fig. 8. The pancreas of Pdk1ΔPanc juvenile mice is hypoplastic. (A, B) At P21, the Pdk1ΔPanc pan
all exocrine cells in the smallest P21 Pdk1ΔPanc pancreatic specimens have less cytoplasm (arr
C). (E) In P21 wild-type pancreata, a few exocrine cells (arrows) or ductal cells (arrowhead)
cells express Ki67 throughout the entire P21 Pdk1ΔPanc pancreatic epithelium, including the s
(arrows in E) have a larger size and more abundant cytoplasm than the exocrine cells of P21
eosin. (E, F) Cell nuclei were stained with hematoxylin. (G, H) Confocal images of frozen se
100 μm (C, D, E, F).expression almost exclusively in the cytoplasm of endocrine cells
(Fig. 9H). In contrast, the islets of P18 Pdk1ΔPanc pancreata had
prominent nuclear Foxo1 expression, presumably in β cells (Fig. 9I).
On the other hand, the wild-type acini (Fig. 9J), the normal-sized
Pdk1ΔPanc acini (data not shown) and the small-sized Pdk1ΔPanc acini
(Fig. 9K) were entirely devoid of Foxo1 expression. This result further
suggests that Pdk1 (and consequently, Akt) does not regulate the
same targets in pancreatic endocrine and exocrine cells.
Discussion
In this study, we report that the conditional deletion of Pdk1 in
mouse pancreatic progenitors results in severe pancreatic hypoplasia
at birth and ensuing hyperglycemia at postnatal stages. We also
provide evidence that these alterations are caused by inadequate
formation of exocrine and endocrine cell masses during pancreas
development. Therefore, we conclude that Pdk1 is a novel, crucial
growth regulator in developing pancreatic tissues.
Pdk1 has multiple roles during pancreas organogenesis
The phenotypic alterations of Pdk1-deﬁcient pancreatic tissues
underscored in our analysis suggest a distinct temporal, cell type-
speciﬁc requirement of Pdk1 activity in the control of cell prolifera-
tion, cell survival, and cell size during pancreas development.
Speciﬁcally, early on in pancreas organogenesis Pdk1 promotes the
proliferation and survival of pancreatic progenitors. After E15.5, these
early roles of Pdk1 segregate into speciﬁc cell lineages: Pdk1
continues to regulate proliferation but not survival in developing β
cells whereas, reciprocally, Pdk1 activity becomes dispensable or
redundant for proliferation, but not for survival, in developing
exocrine cells. Finally, our study also revealed that Pdk1 function is
continuously required in both, the exocrine- and β-cell lineages of the
pre- and postnatal pancreas, to reach and to preserve the proper size
of cells. The lack of appropriate molecular tools precluded investigat-
ing whether Pdk1 also has lineage-restricted functions in endocrine or
exocrine precursors of the early embryonic pancreas.
Our ﬁnding that Pdk1 activity is differentially required in distinct
pancreatic cell types is not unexpected, because in diverse organisms
Pdk1 has been shown to control distinct processes required for organ
growth in a tissue-restricted manner. For instance, in Drosophila
dPdk1 was reported to control the growth of eye or wing imaginal
disks by regulating cell size (Cho et al., 2001). Likewise, in mouse
embryos Pdk1 controls heart size by regulating the growth of
individual cardiomyocytes but not the number of these cells (Mora
et al., 2003). In contrast, Pdk1 enables the expansion of pro-
opiomelanocortin (POMC) cells in the mouse pituitary gland by
promoting the survival of these cells (Belgardt et al., 2008).
In this study we report that the early pancreas of E10.5 Pdk1-
deﬁcient mice is hypoplastic, and we provide evidence that this defect
is a consequence of decreased proliferation and survival of pancreatic
progenitors. These results thus indicate that the PI3K signaling
mediated by Pdk1 is necessary to efﬁciently expand early pancreatic
progenitors. It is quite possible that PI3K signaling cooperates with
other cytokine-mediated pathways during this process, because the
lack of Pdk1 function causes mild, but not severe size reduction in
early pancreatic tissues. One likely partner in this cooperation could
be the activation of MAPK by FGFs, since Bhushan et al. (2001)creas (B) is markedly smaller than this organ of wild-type littermates (A). (C, D) Almost
ows in D) and form smaller acini than those cells of wild-type pancreata (arrowheads in
appear expressing the proliferation marker Ki67 (brown staining). (F) More numerous
mall-sized exocrine cells (arrows). (G, H) The exocrine cells of P21 wild-type pancreata
Pdk1ΔPanc pancreata (arrows in F). (C, D, I, J) Parafﬁn sections stained with hematoxylin-
ctions stained with anti-β-catenin antibodies and DAPI. Scale bar is: 25 μm (G–J) and
Fig. 9. Akt phosphorylation at S-473 is seen in the small exocrine cells in the pancreas of P18–P21 Pdk1ΔPanc mice. (A) Akt phosphorylation at S-473 is negligible in P21 wild-type
pancreata. (B) Akt proteins are abundantly phosphorylated at S-473 in some lobes in the pancreas of P21 Pdk1ΔPanc mice (arrows), or expressed at negligible levels in other lobes of
this mutant organ (arrowheads). (C) Phosphorylation of Akt at S-473 is observed in exocrine acini (ex), but not in islets (isl) or ducts (dc) of P21 Pdk1ΔPanc pancreata. (D, E) The
exocrine cells of P21 Pdk1ΔPanc pancreata with normal size (E) do not express Akt (S473) (D). (F, G) The small exocrine cells of P21 Pdk1ΔPanc pancreata (G) express Akt (S473)
proteins abundantly (F). (H) Cytoplasmic localization of Foxo1 proteins (brown staining) in an islet of P18 wild-type pancreata. (I) Distribution of Foxo1 proteins (brown staining
and arrows) in the cytoplasm and nucleus of an islet of P18 Pdk1ΔPanc pancreata. (J, K) Foxo1 expression is negligible in the exocrine tissue of P18 wild-type (asterisks in J) or
Pdk1ΔPanc (asterisks in K) pancreata. (E, G) Anti-β-catenin antibodies were used to delineate the exocrine cell perimeter. (D, E) and (F, G) are consecutive sections, respectively. Cell
nuclei were stained with hematoxylin (A, B) or with methyl green (C–K). Scale bar is: 25 μm (C–K) and 100 μm (A, B).
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severe pancreas hypoplasia and deﬁcient proliferation of pancreatic
progenitors. It would be important to determine whether signaling
downstream of PI3K/Pdk1 is also affected in the FGF10-deﬁcient
pancreas, because in certain cellular contexts FGFs have been shown
to activate both, MAPK and PI3K (Schlessinger, 2004).
Pdk1 is a novel regulator of pancreatic exocrine cell growth
One of the major, novel ﬁndings of our study is that Pdk1 function
is crucial to expand the population of developing pancreatic exocrine
cells. Interestingly, similar to our results, Kido et al. (2002) reportedthat mice with deﬁcient insulin/insulin-like growth factor signaling
(Insr−/−;Igfr1−/− mice or Igf1−/−;Igf2−/− mice) also had pancreas
hypoplasia due to reduced growth of the exocrine cell mass. The fact
that lack of insulin/insulin-like growth factor signaling or Pdk1
function results in similar phenotypic alterations is not unexpected
because most, if not all, signaling mediated by the insulin receptor or
the insulin-like growth factor receptor converges at Pdk1 (Alessi et al.,
1997). However, one major difference between our study and that of
Kido et al. (2002) is that the pancreas of E17.5 Pdk1ΔPanc embryos
exhibited increased epithelial cell proliferation (including the exo-
crine cells), whereas the pancreas of E18.5 Igf1−/−,Igf2−/− embryos
exhibited reduced cell proliferation. Hence, while we concluded that
297J.J. Westmoreland et al. / Developmental Biology 334 (2009) 285–298Pdk1 is redundant or dispensable for exocrine cell proliferation, Kido
et al. (2002) proposed that insulin/insulin-like growth factor
signaling controls the proliferation of pancreatic exocrine cells. One
possible explanation for this discrepancy is that additional, non-
pancreatic defects accounted for the reduced proliferation observed in
E18.5 Igf1−/−,Igf2−/− pancreatic tissues. Moreover, our results
conclusively demonstrated that Pdk1 activity is required for the
survival and proper size of developing pancreatic exocrine cells. It
remains to be determined whether defective insulin/insulin-like
growth factor signaling also leads to similar alterations, as these
parameters were not evaluated in the study of Kido et al. (2002). On
the other hand, our identiﬁcation of increased cell proliferation in
E17.5 PDK1ΔPanc pancreata also suggests that compensatory prolifer-
ation mechanisms are induced in response to the lack of pancreatic
growth. The nature of this compensatory response is presently
unknown. Finally, our observation that numerous exocrine cells
underwent apoptosis and proliferation in the PDK1ΔPanc pancreas at
E17.5, but not at postnatal stages, favors a requirement of Pdk1
activity for the survival of pancreatic exocrine cells at developmental
stages but not after birth.
We also uncovered that Pdk1 function confers proper size to
individual pancreatic exocrine cells. The regulation of cell size by Pdk1
involves the Akt-mediated activation of mTOR (Hay and Sonenberg,
2008). In numerous cell types, S6K proteins mediate the cell size
responses induced by mTOR via the activation of diverse factors
involved with protein translation and ribosome biosynthesis
(Lachance et al., 2002; Montagne et al., 1999; Ruvinsky and Meyuhas,
2006). Consequently, one could predict that S6K activity regulates the
size of pancreatic exocrine cells. However, a previous study showed
that the lack of S6K1 function reduces the size of β cells, but does not
affect the size of exocrine cells (Pende et al., 2000). Furthermore,
another study suggested that the activity of rpS6 (a target of S6K) is
not necessary for pancreatic exocrine cell growth, because mice
expressing non-phosphorylatable rpS6 (i.e., devoid of activity) had
smaller β cells but normal-sized exocrine cells (Ruvinsky et al., 2005).
It is probable that in exocrine cells S6K2 compensates for the lack of
functional S6K1, or that the size of this cell lineage requires S6K-
targets different from rpS6 (e.g., SKAR, eEF2 kinase or eIF4B)
(Richardson et al., 2004; Ruvinsky and Meyuhas, 2006). Alternatively,
it is also possible that Pdk1 controls exocrine cell size via factors that
do not depend on S6K activity (e.g., the mTORC1-effector eukaryotic
translation initiation factor, eIF4E) (Hay and Sonenberg, 2008).
Further studies are necessary to fully disclose the molecular
mechanisms downstream of Pdk1 function in pancreatic exocrine
cells.
Extensive phosphorylation of Akt at S473 occurs in small exocrine cells
but not in normal-sized exocrine cells of Pdk1ΔPanc postnatal pancreatic
tissues
Two rate-limiting steps in the pathway regulated by PI3K/Akt are
the Pdk1-dependent phosphorylation of Akt at T308 and the
mTORC2-dependent phosphorylation of Akt at S473 (Sarbassov et
al., 2005; Toker, 2008). Due to the lack of anti-p-T308 antibodies
suitable for immunohistochemistry we could not validate Akt
phosphorylation at T308 in wild-type pancreata, or lack thereof in
Pdk1-deﬁcient pancreata. However, we anticipate that the phosphor-
ylation of Akt at T308 is abrogated in islets and Pdk1-deleted exocrine
cells of Pdk1ΔPanc pancreata because this residue is a recognized target
of Pdk1 (Alessi et al., 1997; Stokoe et al., 1997).
We used anti-p-S473 Akt antibodies appropriate for immunos-
taining and discovered that Akt was largely unphosphorylated on
S473 residues in the pancreas of P21-P25wild-typemice. Remarkably,
although the p-S473 form of Akt was absent in normal-sized exocrine
cells, islets, and ducts of the P21-P25 Pdk1ΔPanc pancreata, nearly
every small-sized exocrine cell in these mutant tissues expressed(p-S473) Akt proteins abundantly. These results not only support the
notion that the S473 and the T308 residues of Akt are phosphorylated
independently, but also they favor the hypothesis that Pdk1
negatively regulates the kinase responsible for Akt (S473) phosphory-
lation (Bhaskar and Hay, 2007; Mora et al., 2003). Based on recent
published evidence, we propose that mTORC2 is the kinase that
phosphorylates Akt at S473 in Pdk1-deﬁcient pancreatic exocrine cells
(Bhaskar and Hay, 2007; Huang et al., 2008; Sarbassov et al., 2005).
In partial contrast with our results, it is noteworthy that
Hashimoto et al. (2006) observed expression of p-S473 Akt in islets
of βPdk1 mice, whereas we found that this form of Akt was absent in
islets of Pdk1ΔPanc mice. Although highly speculative, we propose that
abrogating Pdk1 function in β cells before they achieve maturation
somehow affects the activity of mTORC2, whereas eliminating Pdk1 in
fully mature β cells does not inﬂuence mTORC2 function.
Increased phosphorylation of Akt at S473 was previously reported
in extracts of embryonic stem cells or cardiomyocytes lacking Pdk1
activity (Mora et al., 2003; Williams et al., 2000). More recently,
Chalhoub et al. (2009) reported strong (p-S473) Akt immunoreactiv-
ity in glial cells, but not in neurons, in brains of mice lacking functional
Pdk1 in the hippocampus and cortex. This unique result supported the
need of strong feedback mechanisms limiting PI3K signaling in glial
cells to minimize pathological conditions since, different to neurons,
mature glia can be stimulated to re-enter the cell cycle (Chalhoub
et al., 2009). We hypothesize that similar control mechanisms operate
in mature pancreatic exocrine cells to restrict their proliferation, since
we noticed abundant expression of (p-S473) Akt and Ki67 proteins in
exocrine cells, but not in β cells, of Pdk1ΔPanc pancreata.
The study of Hashimoto et al. (2006) reported that in the absence
of Pdk1 function, pancreatic β cells accumulated Foxo1 proteins (a
target of Akt) in the nucleus. Foxo1 increases the expression of the cell
cycle inhibitor p27; thus, these authors hypothesized that the Pdk1-
Akt axis promotes β-cell proliferation via preventing the nuclear
accumulation of Foxo1. In agreementwith this result, in β cells of P18-
P21 Pdk1ΔPanc pancreatic tissues, we also observed that Foxo1 proteins
were largely expressed in the nucleus. In contrast, we did not detect
Foxo1 expression in pancreatic exocrine cells of P18-P21 Pdk1ΔPanc
mice or wild-type mice. These results support the notion that the
pathways regulated by Pdk1 differ in the exocrine- and β-cell lineages
of the pancreas.
Is Pdk1 function necessary to preserve global pancreas homeostasis?
Hashimoto et al. (2006) uncovered that Pdk1 function is necessary
to maintain glucose homeostasis in adult mice because its activity
promotes the survival, proliferation, and proper size of mature
pancreatic β cells. Our detailed characterization of Pdk1ΔPanc pancre-
atic tissues furthered these observations by demonstrating that Pdk1
activity is also necessary to expand the population of pancreatic β
cells during embryogenesis. However, different from its role inmature
β cells, Pdk1 appears to control the size and proliferation, but not the
survival, of developing β cells. Arguably, the survival role of Pdk1
becomes necessary in this lineage only after the cells achieve full
maturation.
The results of this study also revealed that Pdk1 is a central player
in the control of pancreatic exocrine growth. We also showed that,
despite compensatory proliferation, the total exocrine mass of the
Pdk1-deﬁcient pancreas remains decreased at postnatal stages.
Unfortunately, Pdk1ΔPanc mice are not suitable models in which to
test whether defective exocrine growth leads to pancreatic insufﬁ-
ciency, because those animals had to be euthanized at a relatively
young age (1–2 months) due to severe hyperglycemia. Addressing
this important issue should require the speciﬁc inactivation of Pdk1 in
the pancreatic exocrine cell lineage. Another aspect worthy of
investigating is how Pdk1 activity affects pancreatic tumor formation,
particularly because Stanger et al. previously demonstrated that the
298 J.J. Westmoreland et al. / Developmental Biology 334 (2009) 285–298loss of activity of the PI3K negative regulator, PTEN, results in the
formation of preneoplastic lesions in the pancreas (Stanger et al.,
2005).
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